Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Nearly 50 existing non-cancer drugs were found to kill some cancer cell lines in the lab.
Understanding how these drugs kill cancer cells provides new insights into how to defeat this complex disease.
FDA says studies of new breast cancer treatments should allow enrollment of men as well as women.
The way we develop new treatments for cancer does always lead to better survival time, and rarely leads to better quality of life.
Branded drugs with expired patents but without generic competition may keep prices high and ultimately hurt patients.
While this program is intended for brand and generic drugs, we know it will support more efficient development and production of generics.
The accelerated approval pathway may offer a faster route to approval for new treatments in significant, unmet medical needs.
The FDA wants to give prescribers and patients access to the most up-to-date information to guide treatment decisions.
“The result of this progress is that we openly talk about curing cancers that were recently fatal,” says Commissioner Gottlieb.
The agency hopes to make better use of information from patients and providers.
Where appropriate, the FDA supports broader labeling of companion diagnostics.
A win–win for making progress against cancer
The digestive system breaks down all the molecules we eat—except the antibodies we ingest in breast milk.
The findings suggest that existing PRC2 inhibitors, while effective, may be working in a different way than previously believed.
Biosimilar products can provide additional treatment options and create market competition, potentially lowering the costs of treatment.
Jim O’Neill is also interested in immortality. For real.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.